Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Eugene R. Bleecker(Wake Forest University), J. Mark FitzGerald(Vancouver General Hospital), Pascal Chanez(Aix-Marseille Université), Alberto Papi(University of Ferrara), Steven F. Weinstein(California Allergy and Asthma Medical Group), Peter Barker(AstraZeneca (United States)), Stephanie Sproule(AstraZeneca (United States)), Geoffrey Gilmartin(AstraZeneca (United States)), Magnus Aurivillius(AstraZeneca (Sweden)), Viktoría Werkström(AstraZeneca (Sweden)), Mitchell Goldman(AstraZeneca (United States))
The Lancet
September 7, 2016
Cited by 1,366

Abstract


Related Papers

No related papers found

Powered by citation graph analysis